🎉 Congratulations to Dr. Heidi Klepin for receiving the prestigious B.J. Kennedy Geriatric Oncology Award at #ASCO25! It highlights her commitment & leadership in improving care for older adults with cancer through clinical research & practice. Atrium Health Wake Forest Baptist Wake Forest University School of Medicine

🚨 Important Study Alert! 🚨 If you're on immune checkpoint inhibitors (ICIs) for cancer treatment, long-term use of proton pump inhibitors (PPIs) might increase your risk of kidney issues and all-cause mortality. Read more: bit.ly/3FtrwDY #ASCO25

Featured at #ASCO25 👉🏻 abstract 2019. We are so happy to be able to offer this therapy for #pcnsl #lymphoma as part of a trial at Levine Cancer #tirabrutinib

⭐ It’s official! ⭐ Congrats to Dr. Melissa Dillmon on starting her role on the board of ASCO. She’s a dedicated oncologist at Harbin Clinic, now part of the Atrium Health family, who has spent many years in leadership and advocacy roles fighting for patients. #ASCO2025

Education session 📘 🩺 Dr. Erin Crane discusses treatment options for rare uterine cancers: surgery and chemo for early-stage serous carcinomas, targeted therapy for advanced, & surgery, chemo, and radiation for mesonephric-like endometrial. #ASCO2025

Battling financial toxicity through screening 💵 Dr. Greg Knight presents his latest research at #ASCO25 that shows asking our patients regularly about the help they need can lead to finding more solutions for them. Read more: bit.ly/3Zd1ons

Progress in the fight against advanced head and neck cancer! 🧬 Our latest study shows Tumor Mutation Burden (TMB) and specific gene mutations associated with patient response to PD-1 inhibitors, potentially guiding personalized treatments. #ASCO25 Link: bit.ly/3FzyE1w

Neuro-onc study alert 🧠 Ashley Love Sumrall, MD, FACP, FASCO presents research that shows dordaviprone (ONC201) is effective and safe for treating recurrent H3 K27M-mutant diffuse midline glioma. With positive responses in both adults and kids, it offers hope. #ASCO25 Link: bit.ly/4kmIX8v

Older cancer survivors tried muscadine grape extract for 12 weeks. While it didn't beat fatigue or boost quality of life, it did improve physical function & gait speed. Next steps, find out how it affects oxidative stress & inflammation. 🍇 #ASCO25 Link: bit.ly/4kjZGZM

Our largest study yet on #DPYD genotype-guided chemotherapy shows that personalized dosing can help reduce severe side effects and hospitalizations. This means safer, more effective treatment options for patients with DPYD variants. 💊🧬 #ASCO25 Link: bit.ly/4kNW3vi

Pre-treatment DPYD genotyping can save 💵 & reduce severe side effects from fluoropyrimidine therapy. By identifying genetic variants beforehand, hospitals can cut costs & improve patient outcomes. 🏥💊 #ASCO25 Link: bit.ly/4mVOjJw

Our Levine Cancer Atrium Health Wake Forest Baptist crew with the always-inspiring ASCO CEO Clifford Hudis & our incredible leader Robin Zon, MD, FACP, FASCO Dr Zon! #asco2025

Promising results for patients with essential thrombocythemia (ET) 🩸Dr. Ruben Mesa (Ruben A. Mesa, MD) highlights Phase 3 SURPASS-ET trial of ropeginterferon at #ASCO25, offering new hope for ET patients with better blood count control & reduced JAK2 mutation. Link: bit.ly/45zY2i7

Small steps, big impacts for cancer survivors! Our study shows the AH-HA tool significantly boosts CV health discussions and even helps with weight loss. Survivors using AH-HA saw more weight reduction compared to usual care. Atrium Health Wake Forest Baptist #ASCO25 Link: bit.ly/4kG98GF

Ropeginterferon Alfa-2b Demonstrates Superior Efficacy & Safety to Anagrelide as 2L for ET - honored to have shared this yesterday during #ASCO25 ⁦Atrium Health Wake Forest Baptist⁩ Comprehensive Cancer Center ⁦⁦Levine Cancer⁩ ⁦PharmaEssentia⁩ dailynews.ascopubs.org/do/ropeginterf…

Exciting news for childhood cancer survivors! A new AI model using simple 10-second ECGs can predict the risk of developing cardiomyopathy within 5 years. This can help identify those needing early heart screenings. 💖 #ASCO25 Atrium Health Wake Forest Baptist Link: bit.ly/4jskPQl

A possible game-changer for those battling relapsed/refractory multiple myeloma (RRMM). 🩸Our study shows that 33% of patients treated with cilta-cel have remained progression-free for ≥5 years. #ASCO25 Link: bit.ly/4koE3aX

That's a wrap for #ASCO25! We came, we collaborated, we worked to conquer cancer.

Potentially game-changing work underway for multiple myeloma, led by Plasma Cell Pete and presented at #ASCO25 👏👇

Congrats to our cancer program leader Dr. Ruben Mesa (Ruben A. Mesa, MD) on earning the prestigious Ernest Beutler Lecture and Prize! Dr. Mesa has been a pioneer in the groundbreaking research & development of new therapies for myeloproliferative neoplasms (MPNs). Atrium Health Wake Forest Baptist